Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05229588 · ClinicalTrials.gov registry record · Phase 2
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05229588 is a Phase 2 study that has completed, run by HonorHealth Research Institute. The registered enrollment target is 8 participants.
The verdict
NCT05229588, a Phase 2 study, has completed, sponsored by HonorHealth Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.
Interventions
- DRUG Lurbinectedin 4 MG Injection [Zepzelca]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-06-14 |
| Est. Completion | 2025-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05229588
The ClinicalTrials.gov registry entry for NCT05229588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurbinectedin 4 MG Injection [Zepzelca] is the first listed.
NCT05229588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05229588 about?
NCT05229588 is a clinical study titled "Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations". The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.
What is the current status of trial NCT05229588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-06-14. Estimated completion is 2025-08-04.
What interventions are being tested in trial NCT05229588?
The interventions under investigation include: Lurbinectedin 4 MG Injection [Zepzelca] (DRUG).
Who is sponsoring clinical trial NCT05229588?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.